Effect of anti-retroviral fixed-dose combination tenofovir, lamivudine, and evafirenz on lipid profile in HIV/AIDS patients

Dyslipidemia has been recorded in antiretroviral therapy (HAART) naive HIV- and HAART HIV-patients. This study aimed to analyze the effect of Anti-Retroviral Fixed-Dose Combination (FDC) Tenofovir, Lamivudine, and Efavirenz on lipid profile in HIV/AIDS patients. This was a longitudinal observational study using one group pretest and posttest design. Subjects were measured for their lipid profile including total cholesterol, triglyceride, LDL, and HDL before and after 3 months receiving FDC ARV. Twenty subjects involved in this study. The mean total cholesterol before the treatment was 163.30±26.38 mg/dl and after 3-month treatment 183.15±26.36 mg/dl (p = 0.008). The mean of triglyceride before the treatment was 127.75±27.57 mg/dl and after 3 months 154.15±34.43 mg/dl (p = 0.003). The mean LDL before of the treatment was 92.90±27.30 mg/dl and after 3 months 109.95±22.49 mg/dl (p = 0.011) and mean of HDL before the treatment was 45.75±7.22 mg/dl and after 3 months 40.40±5.37 mg/dl (p = 0.003). FDC ARV had a significant effect on lipid profiles. Hence, a baseline lipid profile should be obtained in all HIV infected patients before and during antiretroviral treatment.